0001567619-23-004608.txt : 20230307
0001567619-23-004608.hdr.sgml : 20230307
20230307171500
ACCESSION NUMBER: 0001567619-23-004608
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220610
FILED AS OF DATE: 20230307
DATE AS OF CHANGE: 20230307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cambrian BioPharma Inc
CENTRAL INDEX KEY: 0001797409
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39980
FILM NUMBER: 23713675
BUSINESS ADDRESS:
STREET 1: 228 PARK AVENUE S.
STREET 2: #66643
CITY: NEW YORK
STATE: NY
ZIP: 10003
BUSINESS PHONE: (516) 962-3186
MAIL ADDRESS:
STREET 1: 228 PARK AVENUE S.
STREET 2: #66643
CITY: NEW YORK
STATE: NY
ZIP: 10003
FORMER NAME:
FORMER CONFORMED NAME: Cambrian BioPharma Inc.
DATE OF NAME CHANGE: 20191219
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001829802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 620 PROFESSIONAL DRIVE
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: (240) 243-8000
MAIL ADDRESS:
STREET 1: 620 PROFESSIONAL DRIVE
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4/A
1
doc1.xml
FORM 4/A
X0306
4/A
2022-06-10
2022-06-14
0
0001829802
Sensei Biotherapeutics, Inc.
SNSE
0001797409
Cambrian BioPharma Inc
228 PARK AVENUE S.
#66643
NEW YORK
NY
10003
0
0
1
0
Restricted Stock Unit Grant
2022-06-10
4
A
0
4466
0
A
5235956
D
Stock Option (right to buy)
2.05
2022-06-10
4
A
0
14550
0
A
2032-06-09
Common Stock
14550
14550
D
These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer through such vesting date.
These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the James Peyer's continuous service with the Issuer through such vesting date.
Amendment filed solely to correct the number of shares owned.
Cambrian BioPharma Inc, by: /s/ James Peyer
2023-03-07